RedHill Biopharma reported $25.56M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.63M 596K Jun/2026
Cronos Group USD 67.59M 11.23M Sep/2026
RedHill Biopharma USD 25.56M 6.34M Jun/2026